- Home
- VRDN vs ARWR Comparison
VRDN vs ARWR Comparison
Compare VRDN & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRDN
- ARWR
- Stock Information
- Founded
- VRDN 2006
- ARWR 2003
- Country
- VRDN United States
- ARWR United States
- Employees
- VRDN N/A
- ARWR N/A
- Industry
- VRDN Medical Specialities
- ARWR Biotechnology: Pharmaceutical Preparations
- Sector
- VRDN Health Care
- ARWR Health Care
- Exchange
- VRDN Nasdaq
- ARWR Nasdaq
- Market Cap
- VRDN 1.0B
- ARWR 1.8B
- IPO Year
- VRDN N/A
- ARWR 1993
- Fundamental
- Price
- VRDN $13.92
- ARWR $16.07
- Analyst Decision
- VRDN Strong Buy
- ARWR Buy
- Analyst Count
- VRDN 12
- ARWR 10
- Target Price
- VRDN $38.50
- ARWR $42.13
- AVG Volume (30 Days)
- VRDN 838.2K
- ARWR 1.9M
- Earning Date
- VRDN 05-06-2025
- ARWR 05-12-2025
- Dividend Yield
- VRDN N/A
- ARWR N/A
- EPS Growth
- VRDN N/A
- ARWR N/A
- EPS
- VRDN N/A
- ARWR N/A
- Revenue
- VRDN $302,000.00
- ARWR $545,209,000.00
- Revenue This Year
- VRDN N/A
- ARWR $4,380.43
- Revenue Next Year
- VRDN $21,976.14
- ARWR $66.56
- P/E Ratio
- VRDN N/A
- ARWR N/A
- Revenue Growth
- VRDN 4.86
- ARWR 1436.97
- 52 Week Low
- VRDN $9.90
- ARWR $9.57
- 52 Week High
- VRDN $27.20
- ARWR $30.41
- Technical
- Relative Strength Index (RSI)
- VRDN 55.94
- ARWR 59.58
- Support Level
- VRDN $13.37
- ARWR $14.92
- Resistance Level
- VRDN $14.18
- ARWR $17.19
- Average True Range (ATR)
- VRDN 0.67
- ARWR 0.95
- MACD
- VRDN 0.14
- ARWR 0.11
- Stochastic Oscillator
- VRDN 85.65
- ARWR 70.29
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.